Mustard Biopharma

Pharma manufacturing today is: • Slow (12–18 month lead times) • Capital-intensive (millions upfront for small batches) • Operationally inefficient (30–40% lost capacity annually) • Fragmented across various disconnected factories • Creating fragile centralized supply chains of medicines

We are building the world’s first Autonomous biopharma Smart ‘Dark’ Factory, which is a fully software-defined, AI- native pharmaceutical manufacturing ecosystem that autonomously controls the machines and orchestrates the production process, converting raw materials into finished medicine batches with minimal human intervention. It is a vertically integrated manufacturing architecture we designed from the ground up to control all manufacturing and quality activities with intelligent software.

Biologics are booming, but manufacturing is the bottleneck: 80% of biotech startups face 12-18 month CDMO queues. Global drug shortages hit a 10-year high in 2023. New policies favor localized production. AI and automation now make autonomous pharma manufacturing feasible. Renewable energy is no longer optional. Mustard sits at the intersection of these tailwinds, building a new paradigm for speed, adaptability, and software-first control.

Our competitors cannot follow us without gutting their entire technology stack and cannibalizing existing revenue. That is the moat and why we are going to win.